section]) Estimates include BCG, first and third doses of DTP, third dose of polio vaccine (inactivated poliovirus vaccine or oral poliovirus vaccine), third dose of Hib vaccine
, third dose of HepB vaccine, and first dose of MCV
Hib meningitis has been virtually eliminated in a number of developing countries where Hib vaccine
has been introduced into the routine immunisation programmes (8,9).
Anne Schuchat, director of the CDC's National Center for Immunization and Respiratory Diseases, stressed the "critical importance'" of reinstating the booster dose of Hib vaccine
in children aged 12-15 months, in a July 30 letter to health care providers.
However, use of Hib vaccine
has only recently expanded to low-income countries and pneumococcal vaccine is not yet included in national immunization programs in the developing world, where children bear the highest risk for pneumonia and where most pneumonia-related child deaths occur.
Because of changes in measurement of the Hib vaccine
and the vaccine shortage that occurred from December 2007 to September 2009 (2), state coverage estimates included in this report were based on the series that excludes Hib.
Fortunately, the Hib vaccine
shortage does not appear to have resulted in an increase in the number of disease cases in children less than 5 years of age, said the CDC's Dr.
Carrier-induced epitope suppression also is unlikely to be the cause, as there were no shared carrier proteins between the study vaccine and the Hib vaccine
, he said.
The Hib Vaccine
Team received the Agilient Technologies Foundation Health Award for creating an affordable, synthetic vaccine against the bacteria that can cause meningitis and pneumonia.
Since its inception in 1994, NIS has considered a child aged 19-35 months to be fully vaccinated with Hib vaccine
if the child had received 3 or more doses of any Hib-containing vaccine (3+Hib), regardless of vaccine product type received.
The hiatus of more than 20 years between the introduction of the mumps vaccine in 1967 and that of the Hib vaccine
in 1989 in my view was because the economic incentives to develop vaccines were absent.
However, Hib vaccine
does not cross-protect against other serotypes.
As of September 2016, a total of 191 (99%) of 194 WHO member countries had introduced Hib vaccine
, 190 (98%) had introduced hepatitis B vaccine, 132 (68%) had introduced pneumococcal conjugate vaccine (PCV), and 86 (44%) had introduced rotavirus vaccine into infant vaccination schedules.